Immunocore Holdings (IMCR) Earnings Date & Reports

Key Takeaways

• Immunocore Holdings is expected to report its third quarter (Q3) 2026 results in the first half of November, with Wall Street consensus pointing to a modest net loss per share.
• Earnings per share (EPS) estimates cluster around a loss of $0.10 to $0.17, while revenue forecasts range from roughly $113 million to $153 million, reflecting variance across data providers.
• In the prior quarter (Q2 2026), the company posted revenue of $115.9 million, up 18% year over year, but that figure included a one-time U.S. wholesaler inventory build.
• Management has flagged roughly $120 million in second-half sales rebates tied to a French pricing agreement, a key factor to watch on the income statement.
• Beyond the numbers, investors are focused on KIMMTRAK net sales growth and clinical catalysts, including top-line data from the TEBE-AM Phase 3 trial expected as early as late 2026.
• For more detail on Immunocore's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available on Tickeron.
• To discover automated trading ideas across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

Immunocore Holdings is a commercial-stage biotechnology company whose lead product, KIMMTRAK (tebentafusp), is approved for metastatic uveal melanoma (mUM), a rare eye cancer, in roughly 39 countries. Because KIMMTRAK generates essentially all of the company's revenue, each quarterly report serves as a direct read on commercial execution, pricing dynamics, and market penetration. The third quarter carries added weight this year: management warned that a U.S. wholesaler inventory build in Q2 would unwind and that significant European rebates would pressure the second half. With the stock having declined following its August report, this earnings release will test whether underlying demand momentum can offset those headwinds and reassure investors about the company's path toward sustained profitability.

Earnings Expectations

Analyst expectations for Immunocore's Q3 2026 report vary meaningfully across data providers. Consensus EPS estimates range from a loss of roughly $0.10 to $0.17 per share, while revenue forecasts span approximately $113 million to $153 million. For context, the company reported $103.7 million in revenue in the same quarter a year earlier and $115.9 million in Q2 2026, when EPS came in at a loss of $0.02.

Several factors make this quarter difficult to model. First, management disclosed that Q2 included about $6 million in U.S. wholesaler inventory stocking, which is expected to create a sales headwind in Q3. Second, the company anticipates roughly $120 million in sales-related rebates during the second half of 2026, driven in part by a French pricing agreement. Third, KIMMTRAK penetration in major markets now exceeds 70%, meaning sequential growth is naturally moderating. Investors will therefore pay close attention to net product revenue, gross-to-net adjustments, operating expenses, and cash balance, which stood at roughly $880 million at mid-2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biotech names like Immunocore or building watchlists ahead of earnings, it offers a structured way to surface candidates that match specific criteria.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious. Immunocore shares posted a negative post-earnings drift following the August release, when a slight EPS miss and the disclosure of upcoming rebate pressure weighed on the stock. Since then, analysts have issued mixed revisions: HC Wainwright raised its Q3 EPS estimate while maintaining a Buy rating, while others trimmed price targets, citing competitive threats and moderating growth in the core KIMMTRAK franchise. The market's key concern is not the top line alone but the trajectory of net sales after accounting for rebates and inventory normalization. A print that shows stable or improving net product revenue, combined with clearer commentary on rebate timing, could ease pressure, whereas any sign of softer underlying demand would likely extend the cautious tone.

Forward Outlook and Key Factors to Monitor

Following the report, investors should track several forward-looking items. The first is the shape of KIMMTRAK's growth curve. With penetration above 70% in major markets, the company is shifting its growth story toward label expansion rather than same-market gains. Top-line overall survival data from the TEBE-AM Phase 3 registrational trial in previously treated advanced cutaneous melanoma, which completed enrollment of 540 patients, is expected as early as late 2026 and represents a major potential catalyst.

The second area to watch is the financial impact of rebates. Management's guidance of roughly $120 million in second-half rebates could compress reported revenue growth even if underlying patient demand is healthy. Clarity on the timing and size of these items will help investors separate accounting noise from real commercial momentum.

Third, the broader pipeline deserves attention. The PRISM-MEL-301 Phase 3 trial of brenetafusp in first-line cutaneous melanoma and the ATOM adjuvant uveal melanoma study are progressing, while the company has also expanded into autoimmune disease with a Phase 1 program in type 1 diabetes. Finally, the cash position of approximately $880 million provides runway, but operating cash flow turned negative in early 2026, so investors should monitor expense discipline alongside clinical investment. None of these factors point to a single outcome, and the report will be best read as a progress update on both commercial execution and pipeline timelines.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations